ADAR1 is a novel multi targeted anti-HIV-1 cellular protein

Virology

Volumn 422, Issue 2, 2012, Pages 265-277

  Biswas, Nabanita ^a   Wang, Tianyi ^a   Ding, Ming ^a   Tumne, Ashwin ^a   Chen, Yue ^a   Wang, Qingde ^b   Gupta, Phalguni ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

ADAR1; Antiviral; Cellular protein; HIV 1

Indexed keywords

ADENINE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA 1; GAG PROTEIN; GUANINE; POL PROTEIN; REV PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL NUCLEUS; CLADISTICS; CONTROLLED STUDY; CYTOPLASM; ENZYME ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; TRANSCRIPTION REGULATION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS STRAIN;

ADENOSINE DEAMINASE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BASE SEQUENCE; CELLS, CULTURED; GENE EXPRESSION REGULATION, VIRAL; GENES, ENV; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STRUCTURE, TERTIARY; RNA, VIRAL; RNA-BINDING PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855191405     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.10.024     Document Type: Article

References (44)

1. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
2. Bohnlein E., Berger J., Hauber J. Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: new insights into the domain structure of Rev and Rex. J. Virol. 1991, 65(12):7051-7055.
3. Buchbinder A. The envelope of HIV-1 as a key component to infectivity. Prog. AIDS Pathol. 1990, 2:1-11.
4. Chen Y., Dampf D., Chen M., Kulka K., Volsky D.J., Saha K., Gupta P. Dependence of CD8+ T-cell-mediated suppression of HIV type 1 on viral phenotypes and mediation of phenotype-dependent suppression by viral envelope gene and not by beta-chemokines. AIDS Res. Hum. Retroviruses 2000, 16(2):117-124.
5. Chen Y., Rinaldo C., Gupta P. A semiquantitative assay for CD8+ T-cell-mediated suppression of human immunodeficiency virus type 1 infection. Clin. Diagn. Lab. Immunol. 1997, 4(1):4-10.
6. Clerzius G., Gelinas J.F., Daher A., Bonnet M., Meurs E.F., Gatignol A. ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication. J. Virol. 2009, 83(19):10119-10128.
7. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74(18):8358-8367.
8. Desrosiers R.C., Lifson J.D., Gibbs J.S., Czajak S.C., Howe A.Y., Arthur L.O., Johnson R.P. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 1998, 72(2):1431-1437.
9. Doria M., Neri F., Gallo A., Farace M.G., Michienzi A. Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res. 2009, 37(17):5848-5858.
10. Eckmann C.R., Neunteufl A., Pfaffstetter L., Jantsch M.F. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol. Biol. Cell 2001, 12(7):1911-1924.
11. Felber B.K., Hadzopoulou-Cladaras M., Cladaras C., Copeland T., Pavlakis G.N. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. U. S. A. 1989, 86(5):1495-1499.
12. Hadzopoulou-Cladaras M., Felber B.K., Cladaras C., Athanassopoulos A., Tse A., Pavlakis G.N. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. Virol. 1989, 63(3):1265-1274.
13. Helbig K.J., Lau D.T., Semendric L., Harley H.A., Beard M.R. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005, 42(3):702-710.
14. Hinson E.R., Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(48):20452-20457.
15. Hope T.J., Huang X.J., McDonald D., Parslow T.G. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7787-7791.
16. Horikami S.M., Moyer S.A. Double-stranded RNA adenosine deaminase activity during measles virus infection. Virus Res. 1995, 36(1):87-96.
17. Hough R.F., Bass B.L. Purification of the Xenopus laevis double-stranded RNA adenosine deaminase. J. Biol. Chem. 1994, 269(13):9933-9939.
18. Jiang D., Guo H., Xu C., Chang J., Gu B., Wang L., Block T.M., Guo J.T. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J. Virol. 2008, 82(4):1665-1678.
19. Kim U., Garner T.L., Sanford T., Speicher D., Murray J.M., Nishikura K. Purification and characterization of double-stranded RNA adenosine deaminase from bovine nuclear extracts. J. Biol. Chem. 1994, 269(18):13480-13489.
20. Kowalski M., Potz J., Basiripour L., Dorfman T., Goh W.C., Terwilliger E., Dayton A., Rosen C., Haseltine W., Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987, 237(4820):1351-1355.
21. Lai F., Drakas R., Nishikura K. Mutagenic analysis of double-stranded RNA adenosine deaminase, a candidate enzyme for RNA editing of glutamate-gated ion channel transcripts. J. Biol. Chem. 1995, 270(29):17098-17105.
22. Malim M.H., Bohnlein S., Hauber J., Cullen B.R. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function. Cell 1989, 58(1):205-214.
23. Malim M.H., Cullen B.R. Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol. Cell. Biol. 1993, 13(10):6180-6189.
24. Malim M.H., Hauber J., Le S.Y., Maizel J.V., Cullen B.R. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989, 338(6212):254-257.
25. Malim M.H., McCarn D.F., Tiley L.S., Cullen B.R. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 1991, 65(8):4248-4254.
26. Malim M.H., Tiley L.S., McCarn D.F., Rusche J.R., Hauber J., Cullen B.R. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 1990, 60(4):675-683.
27. Matthews J.C., Hori K., Cormier M.J. Purification and properties of Renilla reniformis luciferase. Biochemistry 1977, 16(1):85-91.
28. Mochizuki N., Otsuka N., Matsuo K., Shiino T., Kojima A., Kurata T., Sakai K., Yamamoto N., Isomura S., Dhole T.N., Takebe Y., Matsuda M., Tatsumi M. An infectious DNA clone of HIV type 1 subtype C. AIDS Res. Hum. Retroviruses 1999, 15(14):1321-1324.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival-application to proliferation and cyto-toxicity assays. J. Immunol. Methods 1983, 65(1-2):55-63.
30. O'Connell M.A., Keller W. Purification and properties of double-stranded RNA-specific adenosine deaminase from calf thymus. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(22):10596-10600.
31. Patterson J.B., Samuel C.E. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 1995, 15(10):5376-5388.
32. Patterson J.B., Thomis D.C., Hans S.L., Samuel C.E. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995, 210(2):508-511.
33. Phuphuakrat A., Kraiwong R., Boonarkart C., Lauhakirti D., Lee T.H., Auewarakul P. Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins. J. Virol. 2008, 82(21):10864-10872.
34. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72(4):2855-2864.
35. Polson A.G., Bass B.L., Casey J.L. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996, 380(6573):454-456.
36. Rosen C.A., Terwilliger E., Dayton A., Sodroski J.G., Haseltine W.A. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(7):2071-2075.
37. Ryter J.M., Schultz S.C. Molecular basis of double-stranded RNA-protein interactions: structure of a dsRNA-binding domain complexed with dsRNA. EMBO J. 1998, 17(24):7505-7513.
38. Samuel C.E. RNA editing minireview series. J. Biol. Chem. 2003, 278(3):1389-1390.
39. Sato S., Wong S.K., Lazinski D.W. Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2. J. Virol. 2001, 75(18):8547-8555.
40. Simon J.H., Miller D.L., Fouchier R.A., Soares M.A., Peden K.W., Malim M.H. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 1998, 17(5):1259-1267.
41. Simon J.H., Sheehy A.M., Carpenter E.A., Fouchier R.A., Malim M.H. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 1999, 73(4):2675-2681.
42. Suspene R., Petit V., Puyraimond-Zemmour D., Aynaud M.M., Henry M., Guetard D., Rusniok C., Wain-Hobson S., Vartanian J.P. Double-stranded RNA adenosine deaminase ADAR-1-induced hypermutated genomes among inactivated seasonal influenza and live attenuated measles virus vaccines. J. Virol. 2011, 85:2458-2462.
43. Taylor D.R., Puig M., Darnell M.E., Mihalik K., Feinstone S.M. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J. Virol. 2005, 79(10):6291-6298.
44. Yang J.H., Luo X., Nie Y., Su Y., Zhao Q., Kabir K., Zhang D., Rabinovici R. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation. Immunology 2003, 109(1):15-23.